Discussion
A new €8 million (about $8.8 million) European research project will support a Phase 2 trial of HER-096, Herantis Pharma’s experimental therapy designed to protect nerve cells and potentially slow Parkinson’s disease progression. The multinational study is expected to enroll about 100 people with newly diagnosed Parkinson’s at…
